Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TK1 | P04183 | 3/20 | 0.34 |
| ▸ | NT5E | P21589 | 1/20 | 0.32 |
| ▸ | TYMS | P04818 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9551996 | 0.88 | DUT (0.59) | DUTMEN1KMT2ATK1TYMS | |
| SCHEMBL2114483 | 0.88 | DUT (0.52) | DUTMEN1KMT2ATK1TYMS | |
| SCHEMBL1687292 | 0.86 | TK1 (0.51) | TK1 | |
| SCHEMBL5486401 | 0.85 | LMNA (0.46) | TK1TYMS | |
| SCHEMBL5086839 | 0.85 | TK1 (0.46) | TK1TYMS | |
| SCHEMBL20840413 | 0.85 | TK1 (0.40) | TK1TYMS | |
| SCHEMBL2027057 | 0.85 | LMNA (0.49) | TK1TYMS | |
| SCHEMBL8892071 | 0.84 | TK1 (0.40) | TK1TYMSCYP3A4 | |
| SCHEMBL442714 | 0.84 | SLC28A1 (0.43) | — | |
| SCHEMBL2030339 | 0.83 | TK1 (0.38) | TK1TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6967079-B2 | Pyrimidine derivatives for labeled binding partners | ISIS PHARMACEUTICALS, INC. (US) | 2005-11-22 | — | — | US | disclosed |
| US-20030207824-A1 | Pyrimidine derivatives for labeled binding partners | MATTEUCCI MARK D (US) | 2003-11-06 | — | — | US | disclosed |
| US-6617437-B1 | Modified oligonucleotide of given formula; useful in diagnostics and therapeutics | ISIS PHARMACEUTICALS, INC. | 2003-09-09 | — | — | US | disclosed |
| EP-0423839-B1 | Polynucleotides and probes useful in solution phase nucleic acid sandwich assay | BAYER AG (US) | 2001-08-16 | — | — | EP | disclosed |
| US-6107039-A | MIXING SAMPLE OF NUCLEIC ACID SEQUENCE TO BE ANALYZED WITH OLIGONUCLEOTIDE PROBE CONTAINING AT LEAST ONE THIOL-PROTECTED PYRIMIDINE NUCLEOTIDE, EXPOSING TO ENDONUCLEASE, AND IDENTIFYING FRAGMENTS HAVING HYBRIDIZED PROBE | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA | 2000-08-22 | — | — | US | disclosed |
| US-6008334-A | MODIFIED PYRIMIDINE NUCLEOSIDES/NUCLEOTIDES WITH PROTECTED THIOL GROUP ATTACHED AT 5 POSITION OF BASE THAT IS NOT INVOLVED IN WATSON-CRICK BASE PARING; FOR USE IN CHEMICAL AND ENZYMATIC SYNTHESIS OF NUCLEIC ACIDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 1999-12-28 | — | — | US | disclosed |
| US-6005096-A | FOR OLIGONUCLEOTIDES THAT ARE MODIFIED TO ENHANCE THE BINDING AFFINITY AND TO BEAR DETECTABLE LABELS; FOR DIAGNOSTIC USE | GILEAD SCIENCES, INC. (US) | 1999-12-21 | — | — | US | disclosed |
| US-5763588-A | Pyrimidine derivatives for labeled binding partners | GILEAD SCIENCES, INC. (US) | 1998-06-09 | — | — | US | disclosed |
| US-5502177-A | POLYCYCLIC STRUCTURE BOUND TO OLIGONUCLEOTIDE, FLUORESCENT LABEL, IMMUNOASSAY | GILEAD SCIENCES, INC. (US) | 1996-03-26 | — | — | US | disclosed |
| US-5434257-A | Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages | GILEAD SCIENCES, INC. (US) | 1995-07-18 | — | — | US | disclosed |
| WO-1995011911-A1 | BINDING COMPETENT OLIGOMERS CONTAINING UNSATURATED 3',5' AND 2',5' LINKAGES | GLAXO WELLCOME INC. (US) | 1995-05-04 | — | — | WO | disclosed |
| EP-0225807-B1 | Solution phase nucleic acid sandwich assay and polynucleotide probes useful therein | CHIRON CORP (US) | 1994-10-19 | — | — | EP | disclosed |
| US-5093232-A | Detection of dna sequences | CHIRON CORPORATION (US) | 1992-03-03 | — | — | US | disclosed |
| EP-0423839-A2 | Polynucleotides and probes useful in solution phase nucleic acid sandwich assay | CHIRON CORPORATION (US) | 1991-04-24 | — | — | EP | disclosed |
| US-4910300-A | Adding additional nucleotide to modified nucleotide at | CHIRON CORPORATION (US) | 1990-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207824-A1 | Pyrimidine derivatives for labeled binding partners | HNRNPH3, NSUN2, HNRNPH1 | DUT 14/4885MEN1 3864/4885KMT2A 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.